Pharming Group

Pharming Group is a global, integrated biotechnology company that develops and commercializes innovative therapies for rare and ultra-rare immunological and genetic diseases. The company utilizes a combination of small molecules and biologics to target underlying disease drivers, underpinned by integrated capabilities spanning clinical development, manufacturing, regulatory affairs, and commercialization. By prioritizing scientific rigor and patient insights, Pharming advances a pipeline focused on areas with significant unmet needs, such as hereditary angioedema (HAE) and activated PI3K delta syndrome (APDS).

The company’s work is dedicated to supporting patients and caregivers by providing reliable, high-quality treatments, including approved therapies like RUCONEST and Joenja. Pharming focuses on creating long-term impact by executing a disciplined commercial strategy and collaborating with the broader rare disease ecosystem. Through its commitment to patient-centered science, the organization seeks to transform early clinical concepts into real-world, life-changing therapeutic options while fostering sustainable growth for its stakeholders.